Reshma P. Shetty - Apr 25, 2024 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
President, COO & Founder, Director, 10%+ Owner
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Apr 25, 2024
Transactions value $
$0
Form type
4
Date filed
4/29/2024, 04:51 PM
Previous filing
Dec 22, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Stock Option Award $0 +5M $0.00 5M Apr 25, 2024 Class A Common Stock 5M $2.50 Direct F1
transaction DNA Stock Option Award $0 +5M $0.00 5M Apr 25, 2024 Class A Common Stock 5M $2.50 By Spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are subject both to time-based and performance-based vesting criteria (the "Founder Options"). The performance-based vesting is tied to the achievement of four specified stock price hurdles within a five-year period, with 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $5.00, 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $7.50, 20% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $10.00 and the remaining 60% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $12.50. If any of the performance-based criteria are achieved during the five-year performance period, the awards will vest on the five-year anniversary of the grant date, subject to the Reporting Person's or spouse's continued employment with Ginkgo on such anniversary.

Remarks:

President, COO & Founder